Results 21 to 30 of about 33,699 (271)

An Insight Into the Aerosolization Pattern of Formoterol Fumarate Dry Powder Inhalation Formulation Actuated Via Two Different Inhaler Devices. [PDF]

Adv Pharm Bull
Purpose: Effective inhaled drug delivery is essential for managing bronchial asthma and chronic obstructive pulmonary disease (COPD). This study compared the aerosolization efficiency of two different dry powder inhalers (DPIs), the Aerolizer and ...
Asadollahi L, Ghanbari R, Abbaspour-Ravasjani S, Hamishehkar H, Nokhodchi A.   +4 more
europepmc   +2 more sources

Glycopyrrolate/formoterol fumarate MDI in mild-to-moderate chronic obstructive pulmonary disease (PIONEER): a protocol for a randomised, double-blind, placebo-controlled trial. [PDF]

BMJ Open Respir Res
Introduction Patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) often experience rapid declines in lung function but are rarely treated early.
Wang FY, Wang ZH, Xu JX, Liang ZY, Ran PX, Zhou YM, Gao Y, Shi WJ, Jiang WY, Li YQ, Zhang DY, Chen RC, Guan WJ, Zhong NS, Zheng JP.   +14 more
europepmc   +2 more sources

Comparison of the efficacy of noninvasive positive pressure ventilation combined with and without budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in the treatment of acute exacerbations of Chronic Obstructive Pulmonary Disease. [PDF]

Pak J Med Sci
Objective: Mechanical ventilation, such as noninvasive positive pressure ventilation (NIPPV), is often used to relieve the symptoms of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but its treatment effect is limited.
Sun J, Xu X, Wang F.
europepmc   +2 more sources

Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow [PDF]

Therapeutic Advances in Respiratory Disease, 2022
Background and aims: Low peak inspiratory flow (PIF) is common following severe exacerbations of chronic obstructive pulmonary disease (COPD). Patients with COPD and low PIF may be at risk of suboptimal delivery of inhaled therapies to the airways ...
Bärbel Huber, Claus Keller, Martin Jenkins, Abid Raza, Magnus Aurivillius   +4 more
doaj   +2 more sources

Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study. [PDF]

Int J Chron Obstruct Pulmon Dis
Background Budesonide/glycopyrronium bromide/formoterol fumarate (BUD/GLY/FOR) single inhaler triple therapy became available to prescribe to patients with severe chronic obstructive pulmonary disease (COPD) in France in 2021.
Deslee G, Fabry-Vendrand C, Salmi E, Poccardi N, Coriat A, Ghout I, Eteve-Pitsaer C, Adderley NJ, Leleu H.   +8 more
europepmc   +2 more sources

Budesonide/glycopyrronium/formoterol fumarate co-suspension metered dose inhaler relieves cough after lobectomy: a randomized controlled study. [PDF]

Transl Lung Cancer Res
Background Cough after pulmonary resection (CAP) has emerged as a prevalent complication. However, existing treatment protocols for CAP lack standardization.
Dong J, Jiang S, Qiu Y, Li J, Cui F, Liang H, Lao S, Xie Z, Huang J, Hao Z, He H, Xv X, Zhang M, He M, Zhang Y, He J, Wang W.   +16 more
europepmc   +2 more sources

Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA [PDF]

, 2018
Pear
Lipworth BJ, Collier DJ, Yasuhiro Gon, Zhong NS, Koichi Nishi, Rong Chen, Sourabh Arora, A. Maes, Shahid Siddiqui, C Reisner, Martin UJ   +10 more
openalex   +6 more sources

Successful Sequential Treatment for Severe Asthma Coexisting COVID-19 via Budesonide/Glycopyrrolate/Formoterol Fumarate [PDF]

International Journal of General Medicine, 2021
Yingjian Liang,* Meizhu Chen,* Cuiyan Tan, Changli Tu, Xiaobin Zheng, Jing Liu Department of Pulmonary and Critical Care Medicine (PCCM), The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, People’s Republic of China*These authors ...
Liang Y, Chen M, Tan C, Tu C, Zheng X, Liu J   +5 more
doaj   +2 more sources

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study. [PDF]

Int J Chron Obstruct Pulmon Dis, 2023
Purpose Triple therapy to prevent exacerbations from chronic obstructive pulmonary disease (COPD) is associated with improved health compared to single and dual-agent therapy in some populations.
Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N, Pollack M.   +11 more
europepmc   +2 more sources

Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS [PDF]

International Journal of COPD, 2021
Fernando J Martinez,1 Gary T Ferguson,2 Eric Bourne,3 Shaila Ballal,4 Patrick Darken,5 Magnus Aurivillius,6 Paul Dorinsky,3 Colin Reisner4 1Joan and Sanford I.
Martinez FJ, Ferguson GT, Bourne E, Ballal S, Darken P, Aurivillius M, Dorinsky P, Reisner C   +7 more
doaj   +2 more sources